Literature DB >> 21933302

Perioperative course of FXIII in children undergoing major surgery.

Thorsten Haas1, Wolfgang Korte, Nelly Spielmann, Jacqueline Mauch, Caveh Madjdpour, Markus Schmugge, Markus Weiss.   

Abstract

BACKGROUND: Acquired deficiency of FXIII because of perioperative hemodilution has been described several times in adults; however, data in children are scarce. We performed a prospective observational trial to evaluate the intraoperative course of FXIII in children undergoing elective major surgery.
METHODS: Blood samples were repeatedly taken from 46 children aged 0.3-16 years undergoing major surgery. Concentrations of FXIII and fibrinogen, thrombelastometry by ROTEM®, and cell count were assessed intraoperatively.
RESULTS: A significant decrease in FXIII concentration (median 60%; IQR 49-69%) was already noted at beginning of surgical procedures, while most ROTEM® traces remain unchanged. FXIII levels further deteriorated intraoperatively to minimal levels of 33% (15-61%). Lowest intraoperative clot strength (ExTEM) was 44 mm (34-50 mm), and fibrinogen plasma levels decreased to minimal levels of 130 mg·dl(-1) (95-160 mg·dl(-1) ). In 43 of 46 children, transfusion therapy was necessary. Despite of transfusion of fresh frozen plasma (cumulative total dose 22 ml·kg(-1) [11-32 ml·kg(-1) ]) in 21 of 46 children, FXIII level remains low in all children till the end of surgery at levels of 39% (20-46%).
CONCLUSIONS: Coagulation factor XIII decreased early during major surgery owing to hemodilution. Overall intraoperative FXIII levels remain low despite of transfusion of fresh frozen plasma.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933302     DOI: 10.1111/j.1460-9592.2011.03709.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  5 in total

1.  Management of Dilutional Coagulopathy during Pediatric Major Surgery.

Authors:  Thorsten Haas; Jacqueline Mauch; Markus Weiss; Markus Schmugge
Journal:  Transfus Med Hemother       Date:  2012-03-08       Impact factor: 3.747

2.  The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro.

Authors:  Christoph Johannes Schlimp; Janne Cadamuro; Cristina Solomon; Heinz Redl; Herbert Schöchl
Journal:  Blood Transfus       Date:  2012-12-13       Impact factor: 3.443

3.  Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia.

Authors:  Jez Fabes; Susan J Brunskill; Nicola Curry; Carolyn Doree; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2018-12-24

Review 4.  Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?

Authors:  Wolfgang Korte
Journal:  J Blood Med       Date:  2014-07-09

5.  Influence of factor XIII activity on post-operative transfusion in congenital cardiac surgery-A retrospective analysis.

Authors:  Fabian B Fahlbusch; Thomas Heinlein; Manfred Rauh; Sven Dittrich; Robert Cesnjevar; Julia Moosmann; Jennifer Nadal; Matthias Schmid; Frank Muench; Michael Schroth; Wolfgang Rascher; Hans-Georg Topf
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.